AI Article Synopsis
- The study aimed to explore how octreotide (OCT), a somatostatin analogue, affects the expression of the CTGF gene in liver cells called hepatic stellate cells (HSCs) in a lab setting.
- OCT was tested on HSCs from rats in various doses to compare gene expression changes with a control group, using RT-PCR to measure results.
- Findings showed that OCT significantly reduces the levels of CTGF and TGF-beta mRNA in HSCs, suggesting its potential as a therapy for preventing liver fibrosis.
Article Abstract
Objective: To investigate the effect of somatostatin analogue-octreotide (OCT) on expression of connective tissue growth factor (CTGF) gene of murine hepatic stellate cells (HSCs) in vitro.
Methods: HSCs separated from Sprague Dawley rats by in situ perfusion and Nycodenz gradient were divided into 5 groups. HSCs in 4 out of 5 groups were co-cultured with octreotide at different dosages, and the remaining group served as control. The expression of CTGF and TGF-beta mRNA were assessed by reverse transcription-polymerase chain reaction (RT-PCR).
Results: OCT down-regulates the expression of CTGF and TGF-beta mRNA in HSCs. The effect is increased with a dose dependent manner.
Conclusions: OCT could exert the inhibitory effect on HSCs by down-regulating the expression of CTGF and TGF-beta. This provides a potential for the prevention and management of hepatic fibrosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!